Kristen Stants - Magenta Therapeutics Chief Officer
Insider
Kristen Stants is Chief Officer of Magenta Therapeutics
| Age | 50 |
| Phone | 857 242 0170 |
| Web | https://www.magentatx.com |
Magenta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2885) % which means that it has lost $0.2885 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6534) %, meaning that it created substantial loss on money invested by shareholders. Magenta Therapeutics' management efficiency ratios could be used to measure how well Magenta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Magenta Therapeutics currently holds 29.96 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Magenta Therapeutics has a current ratio of 10.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Magenta Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Angela MD | Spero Therapeutics | N/A | |
| CPA CPA | NextCure | 61 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Satyavrat CFA | Spero Therapeutics | 52 | |
| MBA BS | CytomX Therapeutics | 46 | |
| W Vernon | Nuvation Bio | 65 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Sumita JD | Instil Bio | 50 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Sandeep MD | Instil Bio | 56 | |
| Kerry Wentworth | Nuvation Bio | 52 | |
| Michael MSBA | NextCure | 64 | |
| Timothy Mayer | NextCure | 60 | |
| David Hanley | Nuvation Bio | 55 | |
| Solomon Langermann | NextCure | 66 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Gary Hattersley | Nuvation Bio | 58 | |
| Hoyoung MD | CytomX Therapeutics | 56 | |
| Christopher Ogden | CytomX Therapeutics | 41 | |
Management Performance
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 |
Magenta Therapeutics Leadership Team
Elected by the shareholders, the Magenta Therapeutics' board of directors comprises two types of representatives: Magenta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Magenta. The board's role is to monitor Magenta Therapeutics' management team and ensure that shareholders' interests are well served. Magenta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Magenta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Caren Deardorf, Chief Officer | ||
| David Nichols, Chief Officer | ||
| Jason DPHIL, CEO, CoFounder | ||
| Catherine Monaghan, Head Operations | ||
| Lisa Olson, Head Officer | ||
| MBA JD, Chief Treasurer | ||
| Jim Haney, Director Relations | ||
| Lyndsey Scull, Director Communications | ||
| Kristen Stants, Chief Officer |
Magenta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Magenta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | (32.66 M) | |||
| Shares Outstanding | 60.66 M | |||
| Shares Owned By Insiders | 2.23 % | |||
| Shares Owned By Institutions | 62.63 % | |||
| Number Of Shares Shorted | 383.03 K | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 0.54 X | |||
| EBITDA | (78.98 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |